Decreased levels of hypoxic cells in gefitinib treated ER(+) HER-2 overexpressing...
MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
http://www.ncbi.nlm.nih.gov/entrez/q...=pubmed_docsum Rhonda |
All times are GMT -7. The time now is 03:48 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021